155 related articles for article (PubMed ID: 32847363)
41. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
42. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
43. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
44. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
[TBL] [Abstract][Full Text] [Related]
45. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
46. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Miyazaki Y; Teramoto Y; Shibuya S; Goto T; Okasho K; Mizuno K; Uegaki M; Yoshikawa T; Akamatsu S; Kobayashi T; Ogawa O; Inoue T
J Clin Med; 2019 May; 8(5):. PubMed ID: 31052459
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
48. Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer.
Cui X; Li C; Ding J; Yao Z; Zhao T; Guo J; Wang Y; Li J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901944
[TBL] [Abstract][Full Text] [Related]
49. Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer.
Zhu S; Ni Y; Wang Z; Zhang X; Zhang Y; Zhao F; Dai J; Wang Z; Zhu X; Chen J; Zhao J; Zeng Y; Chen N; Zeng P; Shen P; Sun G; Zeng H
Oncologist; 2022 Nov; 27(11):e870-e877. PubMed ID: 36067250
[TBL] [Abstract][Full Text] [Related]
50. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Detlefsen AJ; Mesaros CA; Duan L; Penning TM
Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
[TBL] [Abstract][Full Text] [Related]
51. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
52. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer.
Liu Y; Chen Y; Jiang J; Chu X; Guo Q; Zhao L; Feng F; Liu W; Zhang X; He S; Yang P; Fang P; Sun H
Eur J Med Chem; 2023 Feb; 247():115013. PubMed ID: 36566714
[TBL] [Abstract][Full Text] [Related]
53. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
54. Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.
Penning TM; Tamae D
Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):264-70. PubMed ID: 27119752
[TBL] [Abstract][Full Text] [Related]
55. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Kikuchi A; Furutani T; Azami H; Watanabe K; Niimi T; Kamiyama Y; Kuromitsu S; Baskin-Bey E; Heeringa M; Ouatas T; Enjo K
Invest New Drugs; 2014 Oct; 32(5):860-70. PubMed ID: 24981575
[TBL] [Abstract][Full Text] [Related]
56. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Tamae D; Mostaghel E; Montgomery B; Nelson PS; Balk SP; Kantoff PW; Taplin ME; Penning TM
Chem Biol Interact; 2015 Jun; 234():332-8. PubMed ID: 25514466
[TBL] [Abstract][Full Text] [Related]
57. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
58. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
59. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
60. The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer.
Dyshlovoy SA; Menchinskaya ES; Venz S; Rast S; Amann K; Hauschild J; Otte K; Kalinin VI; Silchenko AS; Avilov SA; Alsdorf W; Madanchi R; Bokemeyer C; Schumacher U; Walther R; Aminin DL; Fedorov SN; Shubina LK; Stonik VA; Balabanov S; Honecker F; von Amsberg G
Int J Cancer; 2016 May; 138(10):2450-65. PubMed ID: 26695519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]